Sandoz

US states have asked a federal court in Connecticut for preliminary approval of a settlement with Sandoz over alleged price‑fixing for generics. The agreement covers 43 US jurisdictions and provides for total payments of $400 million over seven years, about $320.6 million as settlement principal and $79.4 million in interest. Sandoz and Fougera Pharmaceuticals, a subsidiary acquired in 2012, are accused of fixing prices and dividing markets; Sandoz denies the allegations. The first payment is due after final court approval, and no decision date has yet been set. » Mere på finanzen.net

Sandoz has opened a new production center for biosimilar active ingredients in Lendava, Slovenia, to increase capacity and flexibility within its European production network. By expanding capacity, the company aims to have more than 100 biosimilars in its portfolio over the long term. » Mere på finanzen.net

Sandoz has received market approval in Canada for a generic version of the diabetes drug semaglutide, authorized as a weekly injection for adult patients with type 2 diabetes. The Canadian market for GLP‑1 drugs is estimated at around $2.6 billion and includes roughly 12 million semaglutide injection pens annually. Sandoz also reports approval in Brazil and is studying a tirzepatide generic in the US; the Canadian approval does not affect its 2026 guidance. » Mere på finanzen.net